Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Medical College of Wisconsin
Astellas Pharma Inc
University of Miami
M.D. Anderson Cancer Center
Henry Ford Health System
Enliven Therapeutics
Massachusetts General Hospital
Jonsson Comprehensive Cancer Center
M.D. Anderson Cancer Center
Centre Antoine Lacassagne
Cardiff University
Cancer Trials Ireland
Shanghai Junshi Bioscience Co., Ltd.
DEKA Biosciences
Jiangsu Hansoh Pharmaceutical Co., Ltd.
National Cancer Institute (NCI)
Hansoh BioMedical R&D Company
Ohio State University Comprehensive Cancer Center
University of Oxford
Jazz Pharmaceuticals
Eli Lilly and Company
Processa Pharmaceuticals
Ono Pharmaceutical Co. Ltd
University of Oxford
National Cancer Institute (NCI)
OHSU Knight Cancer Institute
Gustave Roussy, Cancer Campus, Grand Paris
University of Nebraska
Canadian Cancer Trials Group
Swiss Cancer Institute
Genzada Pharmaceuticals USA, Inc.
Ludwig Institute for Cancer Research
Roswell Park Cancer Institute
University of Washington
University of Wisconsin, Madison
H. Lee Moffitt Cancer Center and Research Institute
Lee's Pharmaceutical Limited
National Institutes of Health Clinical Center (CC)
Adlai Nortye Biopharma Co., Ltd.
Ruijin Hospital
National Cancer Centre, Singapore
Brown University
Asan Medical Center
Yale University
University of Texas Southwestern Medical Center
Albert Einstein College of Medicine
Asan Medical Center
Asan Medical Center
Weill Medical College of Cornell University